Featured Research

from universities, journals, and other organizations

Targeted therapy decreases progression rate in thyroid cancer

Date:
September 19, 2010
Source:
Mayo Clinic
Summary:
The drug pazopanib may help revolutionize the care of patients with metastatic, rapidly progressive differentiated thyroid cancers, say researchers who are publishing findings of a phase II clinical trial.

The drug pazopanib may help revolutionize the care of patients with metastatic, rapidly progressive differentiated thyroid cancers, say researchers at Mayo Clinic who are publishing findings of a phase II clinical trial in The Lancet Oncology.

Related Articles


The researchers studied 37 patients with the most aggressive form of this cancer -- developing in less than 5 percent of patients with differentiated thyroid cancer -- and found that about half (18) patients had a long-lasting response to pazopanib. Of that group, 12 are still alive without disease progression. The median progression-free survival time was 11.7 months, with an overall survival rate of 81 percent at one year.

The researchers say that, to their knowledge, these findings represent by far the highest response rate yet reported in such aggressive cases of differentiated thyroid cancer. They caution however, that this drug is not meant to be used in slow-growing differentiated thyroid cancers and that they cannot assess the survival advantage pazopanib offers to the patients studied.

Determining survival benefit would require a randomized clinical trial testing the agent, which inhibits all three vascular endothelial growth factor (VEGF) receptors, compared to other treatments or a placebo.

"In this group of patients, we would have expected the cancer to have progressed in everyone within six months, but instead the median time to progression was almost a year in response to pazopanib therapy," says Keith Bible, M.D., Ph.D., a medical oncologist and researcher who led the multicenter clinical trial, funded by the National Cancer Institute. Most of the patients treated were enrolled at Mayo Clinic campuses in Minnesota and Florida.

But as encouraging as this response is, it does not come without the potential for significant side effects, Dr. Bible says. The drug dose used in 16 patients had to be lowered because side effects were judged by oncologists to become potentially threatening or debilitating, and two patients experienced significant bleeding. Further, although two patients died in association with pre-existing disease while enrolled in the study, the agent could have contributed in some way, he says.

"Further studies of pazopanib in advanced thyroid cancer remain ongoing at Mayo Clinic and associated cancer centers to continue to learn more about how best to use the drug in these cancers," Dr. Bible says. "Such clinical trials also may provide patients access to this drug, which otherwise may be unobtainable due to cost, given that it is not yet approved for use in thyroid cancers."

Plans are underway for a larger phase III clinical trial with aggressive differentiated thyroid cancer patients that will be centered in Europe, with some sites to be opened in the U.S.

The authors declare no conflicts of interest. The manufacturer of pazopanib (GlaxoSmithKline) did not provide funding or other material support to the researchers and did not have access to the data.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Targeted therapy decreases progression rate in thyroid cancer." ScienceDaily. ScienceDaily, 19 September 2010. <www.sciencedaily.com/releases/2010/09/100918181614.htm>.
Mayo Clinic. (2010, September 19). Targeted therapy decreases progression rate in thyroid cancer. ScienceDaily. Retrieved November 22, 2014 from www.sciencedaily.com/releases/2010/09/100918181614.htm
Mayo Clinic. "Targeted therapy decreases progression rate in thyroid cancer." ScienceDaily. www.sciencedaily.com/releases/2010/09/100918181614.htm (accessed November 22, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, November 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com
Could Your Genes Be The Reason You're Single?

Could Your Genes Be The Reason You're Single?

Newsy (Nov. 21, 2014) Researchers in Beijing discovered a gene called 5-HTA1, and carriers are reportedly 20 percent more likely to be single. Video provided by Newsy
Powered by NewsLook.com
Milestone Birthdays Can Bring Existential Crisis, Study Says

Milestone Birthdays Can Bring Existential Crisis, Study Says

Newsy (Nov. 21, 2014) Researchers find that as people approach new decades in their lives they make bigger life decisions. Video provided by Newsy
Powered by NewsLook.com
Ebola: Life Without School in Guinea

Ebola: Life Without School in Guinea

AFP (Nov. 21, 2014) Following the closure of schools and universities in Guinea because of the Ebola virus, students look for temporary work or gather in makeshift classrooms to catch up on their syllabus. Duration: 02:14 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins